Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Basilea Pharmaceutica's Enterprise Value is CHF571.8 Mil.
Basilea Pharmaceutica's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF49.2 Mil. Therefore, Basilea Pharmaceutica's EV-to-EBIT ratio for today is 11.61.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Basilea Pharmaceutica's Enterprise Value is CHF571.8 Mil.
Basilea Pharmaceutica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF51.0 Mil. Therefore, Basilea Pharmaceutica's EV-to-EBITDA ratio for today is 11.20.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Basilea Pharmaceutica (XSWX:BSLN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Basilea Pharmaceutica's current Enterprise Value is CHF571.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF49.2 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Basilea Pharmaceutica's EV-to-EBITDA for today is:
Basilea Pharmaceutica's current Enterprise Value is CHF571.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF51.0 Mil.
Basilea Pharmaceutica's current Enterprise Value is CHF571.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF232.4 Mil.
Basilea Pharmaceutica's current Enterprise Value is CHF571.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was CHF62.1 Mil.
Basilea Pharmaceutica's current Enterprise Value is CHF571.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was CHF59.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica Enterprise Value Related Terms
Basilea Pharmaceutica Enterprise Value Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Enterprise Value falls into.
Basilea Pharmaceutica Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Basilea Pharmaceutica's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of CHF571.8 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Enterprise Value of CHF571.8 Mil as of Jun. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Enterprise Value too high?
Basilea Pharmaceutica's current Enterprise Value is CHF571.8 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Enterprise Value compare to VRTX and REGN?
Basilea Pharmaceutica's Enterprise Value of CHF571.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Enterprise Value is CHF571.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.38, compared to a current price of CHF51.90 — trading 9.6% below its estimated fair value. The current Enterprise Value is CHF571.8 Mil. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Enterprise Value is CHF571.8 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF51.90 is trading 9.6% below its estimated GF Value™ of CHF57.38.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Enterprise Value: CHF571.8 Mil
GF Value™: CHF57.38 vs. price of CHF51.90 (9.6% below fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score
Get the complete analysis for XSWX:BSLN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
